Thus, the compromised cytotoxicity of CD8+ T cells together with the heterogeneity of tumor cell intrinsic mutations are major obstacles to improve the therapeutic efficacy of checkpoint inhibitors in GBM. The gene discussed is CD8A; the disease is neoplasm.